Phase 1b multi-indication study of anetumab ravtansine (BAY 94-9343) in patients with<br>mesothelin expressing advanced or recurrent malignancies - ARCS-MT (Basket)

Bayer0 个研究点目标入组 9 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•- Availability of tumor tissue for mesothelin expression testing
•- Histologically-confirmed, mesothelin-expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria)
•- At least one measurable lesion according to either RECIST 1.1 or ITMIG modified RECIST 1.1 as applicable
•- Adequate bone marrow, liver, renal and coagulation function
•- LVEF * 50% of the lower limit of normal (LLN) according to local institutional ranges
•- ECOG 0 or 1
•- Availability of additional tumor tissue for further biomarker analysis

•- More than one prior anti-tubulin/microtubule agent
•- Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition
•- Symptomatic CNS metastases and/or carcinomatous meningitis
•- Contraindication to both CT and MRI contrast agents
•- Active hepatitis B or C infection
•- Pregnant or breast-feeding patients
•- Tumor type specific exclusion criteria

发起方